Abstract Objective: To determine which covariates predisposed to deep venous occlusion (DVO) after ultrasound-guided sclerotherapy (UGS) for varicose veins. Design: Ultrasound scans before and at 3 to 7 days after UGS to detect post-procedure deep venous occlusion. Materials: A consecutive series of 1931 treatment sessions in 852 patients treated by a technique for UGS. Methods: Ultrasound examination of the full length of axial deep veins above and below knee before and soon after every procedure. Crude c 2 analysis of all covariates allowed selection of those that showed apparent significant influence. Logistic regression analysis of these then determined which independently predisposed to post-procedure deep venous occlusion. Results: Deep venous occlusion was only observed after UGS using foamed sclerosant and occurred following 28 treatment sessions. No significant difference for risk of deep venous occlusion was observed for patient characteristics or which veins were treated. Logistic regression analysis showed significant independent increased risk in a limb from using highly diluted or undiluted sclerosant (OR 0.55; 95% CI 0.19 to 1.59 for 0.6e1.0% solution, OR 10.45; 95% CI 3.12 to 34.99 for 2-2.3% and OR 0.36; 95% CI 0.07 to 1.74 for 3% solution), treating veins 5 mm diameter (OR 3.70; 95% CI 1.23 to 11.13) and injecting 10 ml of foamed sclerosant for a limb (OR 3.64; 95% CI 1.21 to 10.90).
Introduction
Ultrasound-guided sclerotherapy (UGS) is now widely used to treat superficial venous disease. Its efficacy has been demonstrated but post-procedure ultrasound surveillance has also shown that it can be complicated by deep venous occlusion (DVO). 1 This paper analyses factors relating to the patients, veins and technique that could predispose to the complication in a consecutive series of 1931 treatment sessions for UGS in 852 patients.
Materials and Methods

Patient characteristics
Characteristics of patients treated by UGS in this study have been described previously. 1 One surgeon (KM) was responsible for all procedures performed between January 1999 and April 2007. There were 1931 treatment sessions for 1430 vein systems in 1225 legs of 852 patients. The numbers of treatment sessions according to characteristics of the patients, legs and veins are shown in Table 1 . The majority were female and a wide age range was treated. UGS was either the first procedure chosen, was performed for recurrent varicosities after previous surgery for the veins, or was required to treat distal saphenous veins or tributaries at about 2e3 weeks after endovenous laser therapy. The veins treated were the great saphenous and/or anterior accessory saphenous veins grouped together, small saphenous and thigh extension veins, or tributaries alone without saphenous reflux. Representative diameters of the principal veins were measured by ultrasound before treatment. Only one session was required for adequate treatment for the larger proportion of patients, but a second session about one week later was required for some and three or more sessions for a small number.
Treatment technique
The numbers of treatment sessions according to variations in treatment techniques are shown in Table 2 . No anticoagulation was given prior to June 2002 after which it was decided to give a single prophylactic dose of 40 mg of enoxaparin sodium immediately prior to all procedures. The sclerosants used were 3% polidocinol or 3% sodium tetradecyl sulphate (STS) according to the treating doctor's preference at the time. Liquid sclerosants were used until November 2000 and foam UGS for all subsequent procedures. These were injected undiluted for all liquid sclerosant procedures but were frequently diluted with saline to various concentrations down to 0.6% for foam UGS according to the amount of foam anticipated to be required. Foam was made by a variation of the Tessari technique 2 mixing two parts of fluid with three parts of air between two syringes. The volume of liquid sclerosant injected at each session ranged from 2 to 10 (median 5) ml. The volume of foam sclerosant injected at each session Factors Affecting the Risk of Deep Venous Occlusionranged from 2 to 45 (median 5) ml. Sclerosant was injected through tributaries or into saphenous veins according to which appeared to be the best way to fill the veins. The policy was to inject diseased veins as far distal as possible with a second injection if needed to fill the veins resulting in injection below knee, above knee or both.
Ultrasound Surveillance
All ultrasound examinations in this study were performed by specialist vascular sonographers attached to the unit. Selection of suitable patients was made on the basis of preprocedure ultrasound scanning of all superficial and axial deep veins. Prior to treatment, segments of superficial veins that showed reflux were documented and all axial deep veins were examined to determine whether there were any segment that showed reflux and/or occlusion. Scans were repeated at 3 to 7 days after each treatment session to confirm occlusion of treated superficial veins, detect persistent superficial veins that might need further treatment and to examine all axial deep veins above and below knee for segments of occlusion that were not present before the procedures.
Statistical Analysis
We compared characteristics of treated veins using contingency table analysis, adjusted for clustering based on patient. Odds ratios, with 95% confidence intervals, and P-values were computed using logistic regression with standard errors based on Huber-White sandwich estimates of intra-patient correlation (StataCorp, 2005). We developed a predictive model for deep venous occlusion prevalence by first identifying all statistically significant (P < 0.05) univariate predictors, and then combining these into a single multivariable logistic model, from which we inferred a short list of independent, unconfounded predictors of the risk of deep venous occlusion.
Results
There were no segments of deep venous occlusion detected prior to treatment. Deep venous occlusions were detected after 28 treatment sessions (1.45%). Their site according to the veins treated is shown in Table 3 . There were 16 treatment sessions that led to segments of total occlusion of posterior tibial veins and 12 sessions with partial occlusion of above-knee axial deep veins. All occlusions appeared to be asymptomatic and none was known to progress to clinical venous thromboembolic events. There was one further patient who suffered clinical pulmonary embolism without evidence of deep venous occlusion. The results of univariate c 2 analysis for significant covariates according to patient characteristics and treatment techniques are shown in Tables 1 and 2 . There was apparent significant increased risk of deep venous occlusion for males compared to females, for polidocinol compared to STS, for medium dilution of foamed sclerosant, for vein diameters 5 mm and for volumes of foam injected 10 ml. There was no significant increased risk according to age, side, clinical CEAP classification, treatment for primary or recurrent veins or for residual veins after endovenous laser therapy, presence or absence of pre-treatment deep venous reflux, the veins treated, whether it was the first or a repeat UGS session, the level of injection above or below knee, or whether or not an injection of low molecular weight heparin was given.
The results for multivariable logistic regression analysis for all covariates shown by c 2 analysis to possibly influence results are shown in Table 3 . The persistent significant covariates independently predicting increased risk of deep venous occlusion were medium diluted concentrations of sclerosant compared to highly diluted or undiluted sclerosant (OR 0.55; 95% CI 0.19 to 1.59 for 0.6e1.0% solution, OR 10.45; 95% CI 3.12 to 34.99 for 2e2.3% and OR 0.36; 95% CI 0.07 to 1.74 for 3% solution), treating veins 5 mm diameter (OR 3.70; 95% CI 1.23 to 11.13) and injecting 10 ml of foamed sclerosant for a limb (OR 3.64; 95% CI 1.21 to 10.90). 
Discussion
In this study, deep venous occlusion was only observed after UGS with foamed sclerosant although the numbers treated by liquid UGS were relatively small. The larger proportion occurred in below-knee posterior tibial veins but partial occlusions of above-knee axial deep veins were detected. It was difficult to know whether the occlusions were due to secondary deep vein thrombosis or to foam ''sclerus'' entering the deep veins. It appeared that none of the events led to clinical venous thromboembolic sequelae. The frequency of deep vein occlusion was higher than previously reported 3, 4 but this is likely to be due to the policy of scanning the limbs soon after every treatment session. Crude c 2 analysis suggested that the risk might be increased in males and for polidocinol rather than STS but this did not prove to be significant with logistic regression analysis. There was no significant influence for risk from patient or limb characteristics nor several other aspects relating to treatment technique. Nor was the risk reduced by giving a single dose of low molecular weight heparin and this practice has now been abandoned. Ankle exercise immediately following injection of foam has been suggested as a useful method of preventing deep vein thrombosis after foam sclerotherapy but was not used in this clinical series.
We had previously reported that the long-term success rate was significantly improved by using a 1.5% solution of sclerosant for foam UGS.
1 However, this study shows that the risk of deep venous occlusion is highest for medium concentrations and lowest for 0.6e1% dilution or undiluted 3% sclerosant. Reasons for these findings are not known although Parsi and colleagues have shown that varying the concentration of liquid sclerosants in vitro influence whether they are procoagulant or anticoagulant. 5 The second significant finding was that risk was increased by more than threefold for veins treated that were 5 mm diameter and it may be best to consider other forms of treatment for large diameter veins. The third significant influence shown by logistic regression analysis was that injecting 10 ml of foam in a limb resulted in a more than threefold increased risk for deep venous occlusion. A recent European Consensus group has recommended that the volume used in one session should be less than 10 ml 
